Statistical and practical considerations in designing of immuno-oncology trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Statistical and practical considerations in designing of immuno-oncology trials

Published:2020-09-10 Issue:6 Volume:30 Page:1130-1146
ISSN:1054-3406
Container-title:Journal of Biopharmaceutical Statistics
language:en
Short-container-title:Journal of Biopharmaceutical Statistics

Author:

Mukhopadhyay Pralay¹,Huang Wenmei²,Metcalfe Paul³,Öhrn Fredrik⁴,Jenner Mary⁵,Stone Andrew⁶

Affiliation:

1. Oncology Biometrics, AstraZeneca, Gaithersburg, USA

2. Biostatistics, Moderna, Cambridge, USA

3. Oncology Biometrics, AstraZeneca, Melbourn, UK

4. Early Biometrics and Statistical Innovation, AstraZeneca, Mölndal, Sweden

5. Qi Statistics, Kent, West Malling, UK

6. Stone Biostatistics Limited, Cranage, Crewe, UK

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/10543406.2020.1815035

Reference32 articles.

1. A comparison of two simple hazard ratio estimators based on the logrank test

2. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

3. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

4. Back to basics: explaining sample size in outcome trials, are statisticians doing a thorough job?

5. Statistical issues and challenges in immuno-oncology

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting;Journal of Comparative Effectiveness Research;2024-09

2. Assurance methods for designing a clinical trial with a delayed treatment effect;Statistics in Medicine;2024-06-16

3. Futility monitoring for randomized clinical trials with non-proportional hazards: An optimal conditional power approach;Clinical Trials;2023-06-27

4. Comment on “Non-Proportional Hazards – an Evaluation of the MaxCombo Test in Cancer Clinical Trials” by the Cross-Pharma Non-Proportional Hazards Working Group;Statistics in Biopharmaceutical Research;2023-04-03

5. Designing superiority trials with window mean survival time as a primary endpoint;Statistics in Medicine;2023-03-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3